Defects with a large effect seen in syndromes such as the PMDS or fragile X syndrome, but also mutations affecting high confidence ASD risk genes such as SCN2A and CHD8 [14, 15] will represent primary targets of such new therapies [3]. The gene discussed is SCN2A; the disease is fragile X syndrome.